Michael Smith is a Neurology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12670 Whitehall Dr
Fort Myers, FL 339073619
Telephone
239-936-3554Provider last certified this registry record 10 Jun 2024.
Clinical trials
2 registered studies on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
54 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202529 payments
- UCB, Inc.Program year202514 payments
- Lundbeck LLCProgram year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
80.2%Other antiepileptics13.8%Levetiracetam46%Topiramate37%Lacosamide14%Briviact4%Part D<11 patientsGabapentinoids12.5%Gabapentin78%Pregabalin22%Part D≥83 patients+ 18 more classes in this area
Cardiovascular
10.8%Beta blocker5.7%Propranolol Hcl Er77%Propranolol Hcl23%Part D≥27 patientsStatin5.1%Atorvastatin Calcium84%Rosuvastatin Calcium17%Part D<11 patientsBlood & clotting
4.5%P2Y12 inhibitor2.4%Clopidogrel73%Brilinta27%Part D<11 patientsFactor Xa inhibitor1.2%Eliquis100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Analyzing effectiveness of ongoing natural experiments in telehealth
University of Florida
FY2026$660,082R01HL171387 - Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the gut microbiota-brain-immune axis
University of Florida
FY2026$646,654R01HL132448 - Synthesis of Bioactive Natural Products and Unnatural Congeners
Florida State University
FY2026$366,634R35GM150795
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”